Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress

Mar 24, 2016

Rexahn Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results

Mar 14, 2016

Rexahn Announces $5 Million Registered Direct Offering

Feb 26, 2016

Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma

Feb 8, 2016

Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016

Feb 1, 2016

Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal Cancers Symposium

Jan 25, 2016

New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

Jan 12, 2016

Rexahn Pharmaceuticals’ Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study

Jan 11, 2016

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2016

Jan 5, 2016

Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition

Dec 14, 2015